First new antibiotic in 50 years to tackle superbug
The first new antibiotic in 50 years to tackle a common superbug will be tested on patients.
The drug, which targets one of the bacteria considered to pose the biggest threat to human health, has been hailed as an 'exciting' development in the fight against antibiotic resistance.
On Monday, Roche, the Swiss pharmaceutical giant, announced that it will take zosurabalpin into the third and last phase of testing on humans.
It is the first drug in five decades to show promise of tackling Acinetobacter baumannii, a pathogen which is described as a 'priority' by the World Health Organisation and an 'urgent threat' by the Centers for Disease Control and Prevention, the US national public health agency.
The drug-resistant bacteria disproportionately impact patients who are in the hospital, causing infections such as pneumonia and sepsis.
It is estimated that between 40 and 60 per cent of infected patients, many of whom are immunocompromised because of conditions such as cancer, die as a result of the bug.
One of the reasons it is so difficult to treat is that it has a double-walled 'membrane' protecting it from attack, so it is difficult to get drugs into it and to keep them in, experts say.
Zosurabalpin, which has been developed alongside researchers at Harvard University, targets the 'machine' which stops the outer membrane from forming properly.
It works differently to all existing antibiotics and it is hoped that it could lay the foundations for future drugs.
Michael Lobritz, global head infectious diseases at Roche, said: 'Our goal is to contribute new innovations to overcome antimicrobial resistance, one of the biggest infectious disease challenges to public health.'
The phase-three trial, which it is hoped will start later this year or in early 2026, will look at around 400 patients with a carbapenem-resistant Acinetobacter Baumannii (CRAB) infection who will either receive zosuarbalpin or the current standard of care.
It is hoped that the drug will be approved by the end of the decade.
Larry Tsai, senior vice president and global head of immunology and product development at Genentech, a unit of Roche, said that the drug-resistant bacteria 'are present in every country of the world' .
He said that 'the innovative biology involved in this research could potentially reveal new insights into the structure of bacterial membranes, possibly leading to the discovery of new antibiotics in the future'.
Pharmaceutical companies, including Roche, have in the past been unwilling to pursue new antibiotics because of a difficult market in which the drugs are used sparingly to try and avoid resistance.
However, the UN has warned that if nothing is done to address the issue, drug-resistant diseases could cause 10 million deaths each year by 2050 and cause a worldwide financial crash.
Dr Alistair Farley, scientific lead at the Ineos Oxford Institute, has welcomed zosurabalpin as an 'exciting development' for the field.
'There is an urgent unmet clinical need to develop new antibiotics against priority pathogens such as CRAB where antimicrobial resistance is a major concern,' he said.
Dr Farley added that it 'may provide a route to the development of new drugs'.
Studies showing that it worked 'extremely well' in test-tubes and mice were published in the journal Nature earlier this year.
Prof Laura Piddock, scientific director of the Global Antibiotic Research and Development Partnership, said at the time that it provided 'definite hope' for other hard-to-treat infections.
'What is exciting about this discovery is that one of the building blocks that are part of the outer part of this bacterial cell is disrupted by this new drug,' Prof Piddock said.
Antimicrobial resistance was declared by world leaders to be 'one of the most urgent global health threats' at the UN General Assembly earlier this year.
The declaration committed members to establish independent panels on antimicrobial resistance, as many have done for climate change, and to reduce deaths linked to resistance by 10 per cent by 2030.
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
FPT Proposes Public-Private Partnership Model to Develop Vietnam's Digital Healthcare Ecosystem
HANOI, Vietnam, June 06, 2025--(BUSINESS WIRE)--Global IT services provider FPT and Pharma Group jointly hosted the Healthcare Innovation Forum - HIF 2025. The event served as a multi-stakeholder dialogue platform with a spotlight on breakthrough innovations in science, technology, and AI to accelerate healthcare advancements and drive digital transformation in public health services. The Forum was attended by Vietnam Deputy PM H.E. Le Thanh Long, key government officials, and international guests including U.S. Ambassador Marc Knapper, Swiss Ambassador Thomas Gass, former German Vice Chancellor Dr. Philipp Rösler, and representatives from Japan, Singapore, and Harvard Medical School. Vietnam Deputy PM H.E. Le Thanh Long stressed the urgent need to reform healthcare, outlining five strategies: accelerate digitalization with AI and IoT; boost biotech research; strengthen the pharmaceutical sector; foster public–private partnerships; and expand international cooperation for a modern digital health system. Mr. Darrell Oh, Chairman of Pharma Group, said: "Pharma Group, representing the innovative pharmaceutical industry, reaffirms its commitment to supporting Vietnam in achieving the goals outlined in Vision 2045. Realizing this ambition requires a unified, multi-stakeholder approach. Only through sustained collaboration can policy be translated into impactful, lasting improvements in public health. Investing in healthcare is, ultimately, an investment in Vietnam's most vital asset: its people." Dr. Truong Gia Binh, FPT Chairman, stated: "To accompany Vietnam's new era of advancement, the healthcare sector must achieve breakthroughs in three areas: regulation, innovation, and public–private collaboration. We must shift from restrictive thinking to viewing regulation as a driver of national competitiveness, ensuring faster access to new medicines, like in the U.S. or Japan. Vietnam can become a hub for AI-powered clinical trials and drug development, leveraging its strong tech talent with 1 million IT workers, aiming for half to be AI-proficient. Public–private partnerships must connect hospitals, pharmaceutical firms, and healthcare professionals through shared data platforms. Just as Vietnam rose to global prominence in software, it can now aim to lead in innovative pharmaceuticals - one of the world's most advanced industries." AI in Pharma: A Global Trend and an Opportunity for Vietnam Recent data shows 80% of pharma professionals use AI for drug discovery, with 95% of companies investing in it; and AI can cut drug development time from 5-6 years to one. In clinical trials, AI can reduce costs by 70% and timelines by 80%. Mr. Hoang Viet Anh, FPT Digital Chairman and FPT Telecom Chairman, FPT Corporation, underscored: "AI and GenAI are transforming the pharmaceutical industry, with key benefits including accelerating new drug development and enhancing clinical trials across the value chain." He also called this a key moment for digital transformation, outlining an AI roadmap for Vietnam's pharmaceutical sector through 2028. Plans include a centralized data system and AI lab pilots in 2025, blockchain trials in 2026 to fight counterfeit drugs, and a 20% reduction in drug trial time by 2027, aiming to become ASEAN's leading AI hub by 2028. Achieving Resolution 57 and National Goals for Healthcare Breakthroughs As Vietnam pursues its 2045 high-income vision, healthcare emerges as a key pillar for quality of life, social security, and sustainable growth. The round table discussing critical factors to achieve Resolution 57 objectives emphasized three key messages. Firstly, AI and big data drive healthcare innovation, enabling faster drug development and personalized care. Secondly, bold legal and institutional reforms are essential to match tech advances, including streamlined approvals and flexible data regulations. Lastly, strong public-private collaboration is vital to build a sustainable innovation ecosystem connecting tech firms, hospitals, research institutes, and startups. Mr. Vu Anh Tu, FPT Chief Technology Officer, commented: "AI is set to transform healthcare, and by creating a centralized health data infrastructure and leveraging AI and data analysis for new drug trials, Vietnam can establish advanced clinical research centers, shorten timelines, reduce costs, and expand public access to new medicines. Technology can also enable new healthcare delivery models like telemedicine hospitals to improve primary healthcare and expand public access." He further stated: "FPT is ready to collaborate with startups, major enterprises, and global AI research institutions to address key challenges through AI. This approach will mobilize domestic and international resources to drive breakthroughs in this new era." About Pharma Group Founded in 1998, Pharma Group represents the innovative pharmaceutical industry in Vietnam, comprising 20 member companies from Europe, the United States, and Japan. These companies share a mission to ensure timely and sustainable access to high-quality, safe, and innovative medicines for Vietnamese patients. Pharma Group operates under the European Chamber of Commerce in Vietnam (EuroCham) and is a member of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). It works closely with policymakers and healthcare stakeholders in Vietnam and globally to advance sustainable health policies and initiatives, reduce the time to patient access, and build a favorable and attractive investment environment. About FPT Corporation FPT Corporation is Vietnam's leading technology group, pioneering digital transformation and leading in technology and telecommunications solutions and services. FPT supports clients in over 30 countries and territories in achieving their business development strategies through technology. In the healthcare sector, FPT is committed to building a remote healthcare platform and a comprehensive digital medical ecosystem that delivers fast, convenient, and integrated services for regulators, medical institutions, pharmaceutical companies, pharmacy networks, and the public. Leveraging over a decade of AI research and development, FPT actively integrates AI technologies to enhance healthcare quality and expand access to personalized medical services, particularly through telemedicine and real-time patient health monitoring. In pharmaceuticals, FPT advances the sector by digitizing R&D processes, deploying Advanced Pharmacy Omni-Channel Systems, and developing comprehensive drug management platforms connecting patients, doctors, and pharmacies through electronic medical records. Prominent clients include Long Chau Pharmacy, Hitachi Medical Devices, Olympus, MedAdvisor, Zuellig Pharma, and BrightInsight. View source version on Contacts Media ContactMai Duong (Ms.)FPT CorporationFPT Software PR
Yahoo
5 hours ago
- Yahoo
New Research: Childhood Vaccination Rates Drop Across 1,600 U.S. Counties
Childhood vaccination rates have markedly declined across the U.S. since the start of COVID, according to new Johns Hopkins University research showing 78% of more than 2,000 counties reported drops and the average immunization rate had fallen to 91% — further below the 95% threshold needed for herd immunity While existing Centers for Disease Control and Prevention data has historically shown broadly declining measles-mumps-rubella vaccination rates at the state and national levels, the county-level analysis published this week in JAMA is far more granular. Get stories like this delivered straight to your inbox. Sign up for The 74 Newsletter It provides a 'better understanding of these pockets where you have more exceptionally high risk,' said senior author Lauren Gardner, the director of Johns Hopkins University's Center for Systems Science and Engineering. 'Knowing where there are problem areas,' she added, 'gives policymakers and public health professionals locations to target their limited resources to try and improve vaccination coverage and therefore minimize the potential risk of measles outbreaks.' The country is currently experiencing a deadly measles outbreak that has infected over 1,000 people across 30 states and killed two unvaccinated children. Case numbers this year have already surpassed 2024's total and mark the second-highest number of confirmed cases in a year since the disease was declared eradicated in the U.S. in 2000. Some 96% of reported infections have involved a person who was unvaccinated or whose status was unknown and 13% have resulted in hospitalization. Related Gardner, who also led the data collection efforts behind Johns Hopkins' COVID-19 dashboard, and her team collected county-level, two-dose MMR vaccine rates for kindergarteners from each state's department of health website from 2017 to 2024, where available. Ultimately, they were able to analyze trends in 2,066 counties across 33 states and made all their data available to download. While state level average rates may decline by a few percentage points, the researchers found 130 counties where they dropped by at least 10 percentage points, and in 15 of those counties, they plummeted more than 20. Only four of the states studied — California, Connecticut, Maine and New York — reported an increase in the median county-level vaccination rate. They are currently the only four states that exclusively allow medical — and not philosophical or religious — exemptions to mandatory vaccines for school-aged children. Related Gardner said she pursued the county-level data after observing growing vaccine hesitancy and misinformation. Based on her years of work in the field, she said she was '100% expecting to see [these current outbreaks].' If vaccination rates continue to drop 'measles is likely to return to endemic levels in the US,' according to the Johns Hopkins' report — a concern other experts see as heightened by Robert F. Kennedy Jr. now heading the U.S. Department of Health & Human Services. A well-known vaccine skeptic, Kennedy initially downplayed the measles spread in late February and has been inconsistent in his support of the MMR vaccine. Related Under Kennedy's leadership, the Trump administration released the controversial 'Make America Healthy Again' report on May 22, which misinterpreted studies, cited ones that don't exist and is suspected of being generated in part by artificial intelligence. The report, which involved no pediatricians, questions the safety and importance of some childhood vaccines. 'Despite the growth of the childhood vaccine schedule,' the report reads, 'there has been limited scientific inquiry into the links between vaccines and chronic disease, the impacts of vaccine injury, and conflicts of interest in the development of the vaccine schedule.' Related Paul Offit, the director of the Vaccine Education Center at the Children's Hospital of Philadelphia and a professor of pediatrics at the University of Pennsylvania Perelman School of Medicine, pushed back on these assertions. The issue has been well studied, and there is no evidence of links between childhood vaccines and chronic diseases — including diabetes and autism — said Offit, who is also a voting member of the CDC's Advisory Committee on Immunization Practices. He referenced 24 studies across seven countries and three continents involving thousands of children that show they're at no greater risk of developing autism if they receive the MMR vaccine. Current skepticism is not isolated to the measles vaccine: The Food and Drug Administration, which falls under HHS, recently released updated guidance which no longer recommends the COVID vaccine for healthy children or pregnant women. In response, a top COVID vaccine adviser at the CDC resigned this week, according to reporting from The Washington Post. And across the country, numerous states have introduced legislation to loosen vaccine requirements for school-aged children, opening the door for more parents to opt their kids out. 'I think this is only going to get worse,' Offit said. 'I think vaccines are under attack. You have a secretary of Health and Human Services who will do everything he can during the years that he is in that position to make vaccines less available, less affordable and more feared. … So I think this is a dangerous time to be a child in the United States of America.'
Yahoo
5 hours ago
- Yahoo
FOIA Friday: Connolly questioned public health agency FOIA accessibility before his death
(Photo by Getty Images) One of the less noticed features of the Virginia Way is the long-running tendency of the commonwealth's leaders to conduct their decision-making behind closed doors. While the Virginia Freedom of Information Act presumes all government business is by default public and requires officials to justify why exceptions should be made, too many Virginia leaders in practice take the opposite stance, acting as if records are by default private and the public must prove they should be handled otherwise. In this feature, we aim to highlight the frequency with which officials around Virginia are resisting public access to records on issues large and small — and note instances when the release of information under FOIA gave the public insight into how government bodies are operating. Shortly before his late-May death, U.S. Rep. Gerry Connolly, D-Fairfax, expressed concern about the termination of Centers for Disease Control and Prevention staffers who handled Freedom of Information Act requests. It was one of his final acts as a member of Congress before passing away following an extended battle with cancer. In his letter to the CDC's acting director, Connolly said that 'the elimination of staff responsible for facilitating FOIA strongly implies an effort by the administration to prevent the public from obtaining information about their government that they are entitled to request.' The staff cuts come as FOIA officers at the Food and Drug Administration, National Institutes of Health, and other agencies within the Department of Health and Human Services were also let go. Connolly also pointed out that several outbreaks of infectious disease have been reported across the country. 'Now more than ever, maintaining transparency about the operations of the broader HHS — and CDC in particular — is crucial to understanding the government's capacity to respond to such crises.' Some outbreaks are currently noted on CDC's website, but with no FOIA-dedicated staff to handle records requests, it may be harder for journalists and citizens to seek further information that could aid public health. Records obtained by the Richmond Times-Dispatch show that a former Richmond Fire Department employee spent over $800,000 at a company registered to his home between 2017 and 2024. Reginald Thomas, a former analyst for RFD, used his city credit card, purchase orders and invoices to spend money at RPM Supply Co., LLC. The entity is registered to a house in Henrico County that he and his wife own. Though Richmond city officials did not say how much, if any, of the total was spent on legitimate products or services, they did confirm that he is no longer an employee. His conduct has since become the subject of two investigations — one by Richmond's auditor and another by the city's inspector general. The investigation into Thomas is among the latest actions the city has taken to address a history of funding issues tied to card misuse by employees. This spring, Mayor Danny Avula announced restrictions on employees' use of purchasing cards for several months while leaders re-evaluate how employee spending is handled overall. Last year, the inspector general found that nearly $500,000 in RIchmond tax dollars were wasted or misused through use of employees' cards. The Mercury's efforts to track FOIA and other transparency cases in Virginia are indebted to the work of the Virginia Coalition for Open Government, a nonprofit alliance dedicated to expanding access to government records, meetings and other state and local proceedings. Recently, Virginia's Department of Corrections announced and celebrated low recidivism rates, but not mentioned in the agency's news release was a note from the department's research team suggesting the achievement was due to the effects of COVID-19 on Virginia's court system. Recividism — when former prisoners reoffend and end up back in prison — is a metric law enforcement agencies often use to measure the success of rehabilitation programs or other efforts to lower crime rates. Prison reform advocates and rehabilitation advocates also view these metrics as either calls to action or reasons to celebrate programs that may benefit incarcerated people, their families, and the communities to which they return. The latest announcement from the state focuses on recidivism among former prisoners released between July 2020 and June 2021 and only examines people who returned to prison within three years of release — not those who were rearrested during the same time period, Richmond Times-Dispatch reported. About 17% of released prisoners landed back in prison, while 44% were rearrested, according to the report. While rearrests were higher, those numbers aren't counted as recidivism. Because the state's definition ties recidivism to reincarceration, it is influenced by how quickly courts deliver verdicts — and Virginia's courts were under emergency orders that slowed proceedings until the summer of 2022. 'Re-incarceration rates are lower during follow-up years impacted by COVID-19 due to court closures and sentencing delays,' the research team wrote in its report. Kyle Gibson, a spokesperson for VADOC, acknowledged that recidivism rates were lower due to COVID-19, 'but VADOC cannot conclusively say that the pandemic was the sole cause of the lower rates.' Attorney General Jason Miyares, who is seeking reelection this year, has emphasized on social media that the low recidivism rate supports his tough-on-crime approach as the state's top lawyer. In a post to X, he said there are two approaches to lowering the rate: 'hold violent repeat offenders accountable or let them out early.' 'For four years, I've fought to put violent criminals behind bars while leftist politicians demanded leniency and reduced sentences,' he added. 'We see which approach works.' While the recidivism rates have declined over the past decade, according to a Richmond Times-Dispatch analysis, the time frame that VADOC recently celebrated occurred prior to Miyares taking office. Without city council approval, the city of Roanoke overspent by $5 million last year, WSLS reported. A recent audit of expenditures found that the city's general fund exceeded the final budget. 'We are stewards of taxpayer dollars,' said newer council member Nick Hagen, who joined the city's legislative body after the issues occurred. 'They're not ours — they're the people's.' He suspected staff turnover might be part of the problem with lack of budget oversight. This is because the former city manager had stepped down, a successor was appointed, and a new city council took office. The audit also revealed that much of the overspending came from the Children's Services Act — which funds services for at-risk youth — and the city's fire department, which faced rising overtime costs and implemented pay increases. Still, to ensure spending is justified and remains within budget, WSLS reported that the city claimed to be implementing reforms. There will be more frequent budget reviews going forward, new staff will be hired, and stricter internal protocols will be put in place. Have you experienced local or state officials denying or delaying your FOIA request? Tell us about it: info@ SUPPORT: YOU MAKE OUR WORK POSSIBLE
